Introduction. Since the implementation of the new KAS there are few reports on both single center outcomes in the modern era of transplantation and the use of anti-A₂ titers for the determination of eligibility status. Methods. From a single center's transplant record from 12/2014 to 11/2017 all blood group B patients who received a blood group A₂ or A₂B kidney were identified. Demographic and graft outcome data was also collected. Results. Over the 23-month period since the implementation of KAS our center has performed a total of 20 A₂-to-B single organ kidney transplants (65% male; age 55 + 12; 80% AA). Mean follow-up was 614 + 258 days. Only one patient had an episode of acute cellular rejection and zero patients experienced graft loss. Graft outcomes are summarized in Table 1. Of the patient's transplanted four had high anti-A₂ titer levels of 1:8 (our center's cut off for eligibility) prior to transplant. 12 patients also had concurrent anti-A₁ titer levels prior to transplant, with 75% of these values being >1:8 and outcomes were still favorable.

Conclusions. Transplantation of A₂/A₂B kidneys into blood group B patients is safe. Determination of eligibility by anti-A₂ titers produced outcomes similar to those previously reported using anti-A₁ levels. Transplanting patients with high anti-A₁ titers did not result in adverse outcomes.

CITATION INFORMATION: Radomski S., Rosen-Bronson S., Li D., Awwad M., Vranic G., Javid B., Abrams P., Yi S., Cooper M., Gilbert A. State of the Union: Outcomes of a Single Center's A₂-to-B Transplants Two Years after the Implementation of KAS Am J Transplant. 2017;17 (suppl 3).

« Back to 2018 American Transplant Congress